Intradiscal and intra-articular facet infiltrations with plasma rich in growth factors reduce pain in patients with chronic low back pain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111327/?report=printable 1/12 Low back pain (LBP) is a complex and disabling condition, and its treatment becomes a challenge.
Introduction
Low back pain (LBP) is a complex, personal experience encompassing multidimensional phenomena such as physiologic, sensory, affective, cognitive, behavioral, and sociocultural effects. [1] This endemic condition leads to disability with current estimates of 632 million people affected worldwide. [2] Although in most patients LBP is self-limiting, there is a subset of patients whose symptoms will reemerge labeling the condition as nonspecific, chronic LBP lasting longer than 3 months of evolution. [3] The pain is primarily related to mechanical factors which mediate in muscular strain, intervertebral disc degeneration (IVDD), facet-mediated pain, and radiculopathy though the precise mechanisms remain to be elucidated. Two fundamental spinal structures specialized in both shock-absorbing and load-bearing are facet joints and intervertebral discs (IVD) which in response to mechanical stress, inflammatory synovitis, and degenerative arthritis undergo chronic degenerative process which leads to chronic LBP. [4] A remarkable clinical motivation for reducing pain arises from the need to return patients to their daily routines and improve their life quality. The appropriate treatment of chronic LBP remains a daunting challenge despite advances in the management of pain and inflammation by pharmacological and surgical procedures. Before a surgical procedure is performed, the patient should be offered, an incrementally progressive treatment plan, beginning with a minimally invasive interventional therapy [5] for symptomatic disc herniation and degeneration, and lumbar facet joint arthrosis.
An innovative biologically inspired approach to tissue repair is the application of plasma rich in growth factors (PRGF-Endoret), [6] which has been shown to be an efficient treatment to attenuate knee and hip pain of patients with osteoarthritis (OA) and to improve their clinical condition by reducing joint pain. [7, 8] In light of prior promising results in basic science [9, 10] in preclinical, and in osteoarthritic patients whose chronic pain was significantly reduced, [7, 11, 12, 13, 14] we suggested four synergetic effects of PRGFEndoret on synovial joint diseases, namely, a chondroprotective, anti-inflammatory, cell-phenotype modulation, and joint pain attenuation which make PRGF a potential candidate for treatment of vertebral facet joints and IVDD. [15] The aim of our study was to assess the clinical outcome after one intradiscal, one intra-articular facet, and one transforaminal epidural injection of PRGF-Endoret under fluoroscopic guidance-control carried out in the operating theater setting. 
Subjects and Methods

Study design
The study was designed as an observational retrospective pilot study. Eighty-six patients with a history of chronic LBP and degenerative disease of the lumbar spine who met inclusion and exclusion criteria were recruited between December 2010 and January 2012. Inclusion criteria were patients with LBP and symptoms of lumbago and/or sciatica ongoing for at least 3 months; nonresponse to initial pain management with oral nonsteroidal anti-inflammatory drugs (NSAIDs) and/or myorelaxant drugs; patients with failed back surgery syndrome; and age over 18 years. Patients were excluded from the study in case of acute illness, alcoholism, patients with ongoing labor conflict, or patients with mental illness or psychological conditions related to pain.
A preliminary clinical examination was carried out to characterize and diagnose the LBP, which was confirmed by magnetic resonance imaging or computerized tomography, and to assess the back pain as well. Before receiving the PRGF treatment and at the follow-up visits, patients back pain intensity was assessed using the visual analog scale (VAS).
This study was carried out in accordance with "World medical association Declaration of Helsinki" in its latest revised version (Seoul, 2008) . The study protocol was reviewed and approved by the reference ethics committee. All patients provided written informed consent before entry into the study.
Plasma rich in growth factors preparation
The patients were advised not to eat fatty food in the 6 h before the blood extraction. Twenty minutes before to the induction of sedation with 2.5 mg midazolam in addition to atropine intravenously, 20-36 mL of peripheral venous blood was withdrawn from the patient and collected in 9-mL tubes (TB9) containing sodium citrate (3.8% weight/vol). This blood then was centrifuged (PRGF system IV, BTI-Biotechnology Institute, Vitoria, Álava, Spain) at 580 g for 8 min at room temperature. The 2-mL plasma fraction (F2) located just above the sedimented red blood cells was collected (Endoret Traumatology Kit, BTIBiotechnology Institute, Vitoria, Álava, Spain) in another tube but without aspirating the buffy coat [ Figure 1a ]. This plasma fraction (F2) presents a moderate enrichment in platelets (2-fold the platelet count of peripheral blood) with scarce leukocytes. [16] The upper volume of plasma containing a similar number of platelets as peripheral blood (F1) was collected in another tube. A few minutes before the percutaneous infiltration, the PRGF fraction to be applied was activated by adding 20 μL of PRGF activator (10% weight/vol calcium chloride) per milliliter of PRGF [ Figure 1a ].
Plasma rich in growth factors injection procedure
All treatments were performed by the same experienced orthopedic surgeon. Patients were placed in either prone or lateral position depending on patient circumstances. Using sterile technique, disc, intra-articular facet, and peridural percutaneous PRGF infiltrations were performed under X-ray fluoroscopy with a horizontal C-arch (BV Libra, Philips, Eindhoven, The Netherlands). Briefly, the percutaneous disc infiltration approach was used at an oblique angle between 30° and 45° along the lateral margin of the inferior articular process of the vertebra [ Figure 1b , inserts 1 and 2] and through the neuroforamen while preserving the nerve root. The position of the needle, which had a bent-shaped end (Quincke Chiba Needle, 22-gauge: 8 inch), was guided and confirmed under anteroposterior and lateral fluoroscopic view. Once the needle end was located at the degenerated or herniated disc and checked by infiltrating a little bit of activated PRGF under fluoroscopy, 4 mL of activated PRGF was injected into the nucleus pulposus and the surrounding dehydrated areas while paying careful attention not to allocate more than this PRGF quantity. When we removed the needle from the disc, using the same technical procedure, we performed the peridural infiltration injecting 2 mL of activated PRGF [ Figure 1b , insert 3]. We carried out the spinal facet joints infiltration using the same procedure [ Figure 1c , inserts 1 and 2]. While the patient lay prone, the joints to be injected were located and marked. After cleaning and draping, a 22-gauge spinal needle was inserted until it contacted the capsule of the joint, and then with careful and refined movements, the needle tip entered the joint. Once the needle position was confirmed under fluoroscopy, 0.5 mL of activated PRGF was injected into each of the facet joints.
The patient was observed for 1 h after the procedure to monitor for any undesirable reaction. All patients were asked to avoid strenuous activities in the ensuing 3 days. Patients receive antibiotic therapy during 1 week. Additional medical therapy or physiotherapy and the intake of any type of NSAID or painkilling medication were considered an exclusion criterion.
Evaluation and follow-up
Pain assessment was determined using a VAS, with a line whose ends are labeled as the extremes: Score of 0 denoting "no pain" and score of 10 denoting "pain as bad as it could be." [1, 17] The VAS score was evaluated at the first visit before (Baseline) and after the procedure at 1, 3, and 6 months. Reduction in VAS score was considered the outcome of the interventional therapy with PRGF.
Pain relief over time was categorized as excellent (0-3 score in VAS scale), moderate (VAS 3.1-6.5), and ineffective (VAS 6.6-10). [5] The safety data were also collected. All adverse major and minor events were assessed and documented at each visit.
Statistical analysis
Descriptive statistics were performed using absolute and relative frequency distributions for qualitative variables and mean values and standard deviations for quantitative variables. Different normality tests (Kolmogorov-Smirnov and Shapiro-Wilk) were performed on each variable sample. The nonparametric Friedman statistical test was used to determine the possible differences between baseline and different follow-up time points on pain reduction after treatment. Statistical significance level was set on P < 0.05. SPSS version 15.0 for Windows statistical software package (SPSS Inc., Chicago, IL, USA) was used for all statistical analysis.
Results
Study subjects
A total of 86 patients, 47 females (median age 58; age range, 22-81 years) and 39 males (median age 55; age range, 29-79 years) were treated and evaluated.
Clinical outcome after plasma rich in growth factors infiltration
The postprocedure pain reduction assessed by VAS showed a statistically significant drop from 8.4 ± 1.1 before the treatment to 4.0 ± 2.6, 1.7 ± 2.3, and 0.8 ± 1.7 at 1, 3, and 6 months after the treatment, respectively, with respect to all the time evaluations (P < 0.0001) except for the pain reduction between the 3 and 6 months whose significance was lower (P < 0.05) [ Figure 2 ]. Over time, the percentage of pain reduction was gradual until reaching 90% at the end of follow-up (6 month).
The analysis of the VAS over time showed that after the 1 month, 38.4% of patients had excellent (VAS 0-3) pain relief, 44.2% responded moderately (VAS 3.1-6.5), whereas the treatment had been ineffective in 17.4% (VAS 6.6-10). At 3 month, 79.1% of patients had excellent pain relief, 14% had moderate relief, and for 7% had the pain relief was ineffective. At the end point of the study (6 months), 90.7% of patients showed an excellent score, 8.1% showed a moderate VAS score, and 1.2% of patients were included in the ineffective score [ Figure 3 ]. Although the analysis of VAS throughout the follow-up revealed a significant and sustained improvement of clinical condition, the largest pain reduction was attained in the 1 month after the procedure (53% over a total of 90%).
Safety data
There were no major adverse events. None of the patients showed serious adverse effects after the treatment or during the ensuing days, apart from headache (five patients), soreness, or local skin bruising (seven patients).
Discussion
The results of the present study showed that a minimally invasive therapy consisting of PRGF-Endoret infiltrations of IVD and facet joints in patients with chronic LBP resulted in a significant pain reduction assessed by VAS. At the end of follow-up (6 month), 90.7% of patients showed a pain value of 0-3 in the VAS score, which is considered "excellent" in the literature. [5] The pain reduction of 90% at the end of 6 month is consistent with the values published by Sánchez et al. [7] for the treatment of OA of the hip with PRGF infiltration, and comparable to the values reported by Becker et al. [18] using epidural perineural injections of autologous conditioned serum on patients with lumbar radicular compression, and substantially better than the pain relief shown by infiltrating methylprednisolone in the lumbar facet joints, [19] triamcinolone in epidural perineural injections, [18] or betamethasone in periganglionar infiltration [5] in patients with LBP. Nevertheless, the course of treatment reported by Chatuverdi el al. [19] reached a pick of 93% of responders at 4 week of treatment and then declined to 62.5% at 3 month of treatment, an outcome which is no consistent with our results.
Although the relative contribution of various structures in chronic LBP is varied, the pain source commonly is attributed to inflammatory response of facet joints and/or disc degeneration and herniation cells due to mechanical stressful stimuli. [19] Facet joints and IVD undergo chronic degenerative process in response to nonphysiological mechanical stresses, bringing about collagens and aggrecans cleavage, a decrease of collagen and proteoglycan synthesis, an increase of proteases and cell death which parallels to articular cartilage degeneration in OA and whose clinical hallmark is joint pain. [20] There are several potential mechanisms by which PRGF-Endoret infiltrations might either suppress or slow down the progress of IVD and facet degeneration. PRGF-Endoret is an autologous product that conveys a mimetic biomaterial, namely, fibrin, which is embedded with a pool of growth factors (FGF, platelet-derived growth factor [PDGF], insulin-like growth factor-1 [IGF-1], vascular endothelial growth factor, transforming growth factor-β [TGF-β], hepatocyte growth factor [HGF], connective tissue growth factor [CTGF], and nerve growth factor) stemmed from activated platelets and plasma and acting as a biological scaffold from which a sustained and a gradual delivery of growth factors is released at the dysfunctional and degenerate sites instead of as a bolus delivery modality. Furthermore, a proteomic characterization study of PRGF fibrin matrix [21] reported a significant representation of acute-phase proteins, a strong network of interconnected proteins linked to the NF-kB pathway. This pathway is in part responsible for the inflammatory response of stressed cells such as chondrocytes, tenocytes, fibroblasts, and macrophages. In addition, both IVD and facet joints share many developmental, functional, and biological features with articular cartilage and synovial joints. [22] In vitro, several growth factors present in platelet-rich plasma (PRP) such as TGF-β, IGF-1, and CTGF have been shown to exert a powerful effect on extracellular matrix (ECM) synthesis and proliferation in IVD. [23, 24] Furthermore, PDGF and IGF1 have been shown to exert a cell survival action on IVD cells. [25] In addition, PRP through TGF-β or as a PRP whole product has been shown to promote the synthesis of ECM components such as proteoglycans and collagen in human nucleus pulposus cell cultures. [22, 26] More importantly, PRP administration using biodegradable gelatin hydrogel microspheres into degenerated IVD animal model resulted in a preservation of water and disc height, suppression of the IVD degeneration progression, and a synthesis of proteoclycans 8 weeks after the treatment, highlighting the importance of both delivering growth factors in a sustained and gradual manner and the effectiveness for early IVD degeneration intervention. [27, 28] Similar regenerative effects have been reported applying PRP on degenerative disc disease in animal models. [29] Inflammation is a term that encompasses clinical, physiological, cellular, and molecular phenomena, with pain being the hallmark or the tip of iceberg underlying pro-inflammatory cytokine release, ECM catabolism, and cell death. Thus, pain and inflammation are flip sides of the same coin, namely, tissue damage. Data coming from animal studies strongly suggest that pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 are pivotal for the onset and maintenance of pain mainly stemmed from the damaged peripheral tissues. [30] In contrast, anti-inflammatory cytokines such as IL-4 and IL-10 have analgesic properties. [30] Some components present in PRGF-Endoret (HGF, LXA4, PF4, IGF-1, PDGF, and TGFβ) [10, 31, 32, 33, 34] inhibit the NF-kB signaling pathway in several cell lineages including macrophages, chondrocytes, and fibroblasts. NF-kB plays an important role in mediating the gene expression of pro-inflammatory cytokines such as TNFα, IL-1β, PGE2, and COX-1 and COX-2. [35] As a consequence, it is reasonable to consider that PRGF-Endoret could exert an antiapoptotic, ECMprotective, anti-inflammatory, and pain reduction effect in a similar manner as in knee and hip synovial joints. [13, 14, 36] In macrophages, the inhibition of the NF-kB might contribute to the polarization from M1 to M2 phenotype, thereby favoring the resolution of inflammation and generating a switch in the ECM from a pro-inflammatory and algesic milieu to an anti-inflammatory and analgesic context. Furthermore, the in situ generate fibrin matrix would be gradually removed as a result of local activation of the tissue plasminogen activator/plasminogen system. This fibrinolytic remodeling process overlaps with the homing of survival fibrochondrocytes and migratory mesenchymal stem cell, which might had been attracted by chemoattractants such as SDF-1, HGF, IGF-1, TGFβ, or bFGF sequestered within the fibrin matrix and gradually released during the fibrinolytic remodeling process. [37] This study has several drawbacks. The absence of a control (placebo) group in this study is certainly a limitation. There are other weaknesses in our study as to we did not perform a previous diagnostic block for patients' selection, and therefore our diagnosis and selection of patients relied on a careful clinical examination. Another drawback to this study is the lack of measurement of physical activity levels before and after the treatment. Last but not the least, to limit the bias of a single assessment, the self-reported VAS pain scale should have been associated with other health survey questionnaires which encompass pain and functional evaluation. In the light of several limitations of our research, a randomized controlled clinical trial is considered imperative.
Conclusions
Taking into account these limitations and in the light of our preliminary data, we suggest that fluoroscopyguided infiltrations of IVD and facet joints with plasma rich in growth factors could be an alternative therapy in patients with chronic low back. To the best of our knowledge, the present article is the first description of a PRP facet joint infiltration as a complementary approach to IVD infiltration in the LBP treatment.
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